Biology of Eosinophils

Middleton's Allergy: Principles and Practice: Eighth Edition

Volumn 1-2, Issue , 2014, Pages 265-279

  Kita, Hirohito ^a   Bochner, Bruce S ^b  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937723835     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-08593-9.00017-6     Document Type: Chapter

References (99)

1. Ehrlich P Beiträge zur kenntnis der granulierten bindegewebszellen und der eosinophilen leucocyten. Arch Anat Physiol 1879, 3:166-182.
2. Rothenberg ME, Hogan SP The eosinophil. Annu Rev Immunol 2006, 24:147-174.
3. Rosenberg HF, Phipps S, Foster PS Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007, 119:1303-1310.
4. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008, 38:709-750.
5. Bochner BS, Gleich GJ What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol 2010, 126:16-25.
6. Park YM, Bochner BS Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res 2010, 2:87-101.
7. Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 2010, 40:563-575.
8. Shamri R, Xenakis JJ, Spencer LA Eosinophils in innate immunity: an evolving story. Cell Tissue Res 2011, 343:57-83.
9. Eosinophils in health and disease 2012, Elsevier, New York. J.J. Lee, H.F. Rosenberg (Eds.).
10. Ackerman SJ, Bochner BS Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007, 27:357-375.
11. Miyajima A, Kitamura T, Harada N, Yokota T, Arai K Cytokine receptors and signal transduction. Annu Rev Immunol 1992, 10:295-331.
12. Pazdrak K, Olszewska-Pazdrak B, Stafford S, Garofalo RP, Alam R Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med 1998, 188:421-429.
13. Humbles AA, Lu B, Friend DS, et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002, 99:1479-1484.
14. Swaminathan GJ, Weaver AJ, Loegering DA, et al. Crystal structure of the eosinophil major basic protein at 1.8 A: an atypical lectin with a paradigm shift in specificity. J Biol Chem 2001, 276:26197-26203.
15. Plager DA, Loegering DA, Weiler DA, et al. A novel and highly divergent homolog of human eosinophil granule major basic protein. J Biol Chem 1999, 274:14464-14473.
16. Davis MD, Plager DA, George TJ, et al. Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol 2003, 112:988-994.
17. Rosenberg HF, Dyer KD, Domachowske JB Eosinophils and their interactions with respiratory virus pathogens. Immunol Res 2009, 43:128-137.
18. Gleich GJ, Loegering DA, Bell MP, et al. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 1986, 83:3146-3150.
19. Yang D, Chen Q, Su SB, et al. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008, 205:79-90.
20. Wu W, Samoszuk MK, Comhair SA, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest 2000, 105:1455-1463.
21. Gundel RH, Letts LG, Gleich GJ Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991, 87:1470-1473.
22. Kita H Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev 2011, 242:161-177.
23. Ohno I, Lea RG, Flanders KC, et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGFβ1). J Clin Invest 1992, 89:1662-1668.
24. Lacy P, Abdel-Latif D, Steward M, et al. Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects. J Immunol 2003, 170:2670-2679.
25. Dyer KD, Handen JS, Rosenberg HF The genomic structure of the human Charcot-Leyden crystal protein gene is analogous to those of the galectin genes. Genomics 1997, 40:217-221.
26. Nakajima T, Matsumoto K, Suto H, et al. Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells. Blood 2001, 98:1127-1134.
27. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010, 125:1237-1244.
28. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils. I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002, 169:6452-6458.
29. Wilson TM, Maric I, Shukla J, et al. IL-5 receptor alpha levels in patients with marked eosinophilia or mastocytosis. J Allergy Clin Immunol 2011, 128:1086-1092.
30. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008, 121:1484-1490.
31. Na HJ, Hudson SA, Bochner BS IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils. Cytokine 2012, 57:169-174.
32. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ IgA-induced eosinophil degranulation. J Immunol 1989, 142:2393-2400.
33. Gounni AS, Lamkhioued B, Ochial K, et al. High-affinity IgE receptor on eosinophils is involved in defense against parasites. Nature 1994, 367:183-186.
34. Kita H, Kaneko M, Bartemes KR, et al. Does IgE bind to and activate eosinophils from patients with allergy?. J Immunol 1999, 162:6901-6911.
35. Seminario MC, Saini SS, MacGlashan DW, Bochner BS Intracellular expression and release of FcεRIa by human eosinophils. J Immunol 1999, 162:6893-6900.
36. Kayaba H, Dombrowicz D, Woerly G, et al. Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation. J Immunol 2001, 167:995-1003.
37. Saini SS, Klion AD, Holland SM, et al. The relationship between serum IgE and surface levels of FcεR on human leukocytes in various diseases: correlation of expression with FcεRI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol 2000, 106:514-520.
38. Dyer KD, Percopo CM, Xie Z, et al. Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor. J Immunol 2010, 184:6327-6334.
39. Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J 2012.
40. Singh RK, Gupta S, Dastidar S, Ray A Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010, 85:336-349.
41. Pease JE, Williams TJ Chemokines and their receptors in allergic disease. J Allergy Clin Immunol 2006, 118:305-318.
42. Kvarnhammar AM, Cardell LO Pattern-recognition receptors in human eosinophils. Immunology 2012, 136:11-20.
43. Lotfi R, Herzog GI, DeMarco RA, et al. Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol 2009, 183:5023-5031.
44. Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nature Med 2008, 14:949-953.
45. Matsuwaki Y, Wada K, White TA, et al. Recognition of fungal protease activities induces cellular activation and eosinophil-derived neurotoxin release in human eosinophils. J Immunol 2009, 183:6708-6716.
46. Munitz A, Levi-Schaffer F Inhibitory receptors on eosinophils: a direct hit to a possible Achilles heel?. J Allergy Clin Immunol 2007, 119:1382-1387.
47. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012, 135:327-336.
48. Hudson SA, Bovin N, Schnaar RL, Crocker PR, Bochner BS Eosinophil-selective binding and pro-apoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6'-sulfated sialyl Lewis X. J Pharmacol Exp Ther 2009, 330:608-612.
49. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009, 15:368-373.
50. Hamann J, Koning N, Pouwels W, et al. EMR1, the human homolog of F4/80, is an eosinophil-specific receptor. Eur J Immunol 2007, 37:2797-2802.
51. 4 receptor on human eosinophils: role in eosinophil chemotaxis. J Recept Signal Transduct Res 2002, 22:431-448.
52. Muller T, Vieira RP, Grimm M, et al. A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol 2011, 44:456-464.
53. Muller T, Robaye B, Vieira RP, et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy 2010, 65:1545-1553.
54. Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999, 103:1719-1727.
55. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 2000, 105:945-953.
56. Conner E, Bochner BS, Brummet M, Beck LA The effect of etanercept on the human cutaneous allergic response. J Allergy Clin Immunol 2008, 121:258-260.
57. Beck LA, Dalke S, Leiferman KM, et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 1997, 159:2962-2972.
58. Menzies-Gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002, 169:2712-2718.
59. Gonzalo JA, Lloyd CM, Kremer L, et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation - the role of T cells, chemokines, and adhesion receptors. J Clin Invest 1996, 98:2332-2345.
60. Berkman N, Ohnona S, Chung FK, Breuer R Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001, 24:682-687.
61. Na HJ, Hamilton RG, Klion AD, Bochner BS Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8. J Immunol Methods 2012, 383:39-46.
62. Saenz SA, Taylor BC, Artis D Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev 2008, 226:172-190.
63. Alam R, Forsythe P, Stafford S, Fukuda Y Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 1994, 179:1041-1045.
64. Dvorak AM, Furitsu T, Letourneau L, Ishizaka T, Ackerman SJ Mature eosinophils stimulated to develop in human cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. Part I. Piecemeal degranulation of specific granules and distribution of Charcot-Leyden crystal protein. Am J Pathol 1991, 138:69-82.
65. Persson CG, Erjefalt JS Eosinophil lysis and free granules: an in vivo paradigm for cell activation and drug development. Trends Pharmacol Sci 1997, 18:117-123.
66. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ IgA-induced eosinophil degranulation. J Immunol 1989, 142:2393-2400.
67. Mattes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002, 195:1433-1444.
68. Lee JJ, Dimina D, Macias MP, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004, 305:1773-1776.
69. Yu C, Cantor AB, Yang H, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002, 195:1387-1395.
70. Walsh ER, Sahu N, Kearley J, et al. Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma. J Exp Med 2008, 205:1285-1292.
71. Jacobsen EA, Ochkur SI, Pero RS, et al. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J Exp Med 2008, 205:699-710.
72. Fulkerson PC, Fischetti CA, McBride ML, et al. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci USA 2006, 103:16418-16423.
73. Chu VT, Frohlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011, 12:151-159.
74. Wu D, Molofsky AB, Liang HE, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
75. Martin C, Le Goff L, Ungeheuer MN, Vuong PN, Bain O Drastic reduction of a filarial infection in eosinophilic interleukin-5 transgenic mice. Infect Immun 2000, 68:3651-3656.
76. Specht S, Saeftel M, Arndt M, et al. Lack of eosinophil peroxidase or major basic protein impairs defense against murine filarial infection. Infect Immun 2006, 74:5236-5243.
77. Bascom R, Pipkorn U, Proud D, et al. Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989, 84:338-346.
78. Pereira S, Clark T, Darby Y, et al. Effects of anti-eotaxin monoclonal antibody CAT-213 on allergen-induced rhinitis. J Allergy Clin Immunol 2003, 111:S268.
79. Gevaert P, van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011, 128:989-995.
80. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715-1721.
81. Bochner BS Verdict in the case of therapies versus eosinophils: the jury is still out. J Allergy Clin Immunol 2004, 113:3-9.
82. Nair P, Pizzichini M, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
83. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
84. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184:1125-1132.
85. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:1336-1343.
86. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
87. Gauvreau GM, Boulet LP, Cockcroft DW, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952-958.
88. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112:1029-1036.
89. Lefort J, Nahori MA, Ruffie C, Vargaftig BB, Pretolani M In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs. J Clin Invest 1996, 97:1117-1121.
90. Song DJ, Cho JY, Lee SY, et al. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol 2009, 183:5333-5341.
91. Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 118:1312-1319.
92. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010, 59:21-30.
93. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012, 129:456-463.
94. Kagalwalla AF, Akhtar N, Woodruff SA, et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol 2012, 129:1387-1396.
95. Mestas J, Hughes CC Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
96. Lee JJ, Jacobsen EA, Ochkur SI, et al. Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red. J Allergy Clin Immunol 2012, 130:572-584. ".
97. Stelts D, Egan RW, Falcone A, et al. Eosinophils retain their granule major basic protein in a murine model of allergic pulmonary inflammation. Am J Respir Cell Mol Biol 1998, 18:463-470.
98. Denzler KL, Borchers MT, Crosby JR, et al. Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation. J Immunol 2001, 167:1672-1682.
99. Pearce EJ, Sher A Functional dichotomy in the CD4+ T cell response to Schistosoma mansoni. Exp Parasitol 1991, 73:110-116.